📖
Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.
Le Scouarnec L, Bouteloup V, Grasset L, Planche V, Chêne G, Dufouil C, MEMENTO Study Group

Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in J Prev Alzheimers Dis.

Advertisement
SPONSOR CONTENT
Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.
Author / Organization Le Scouarnec L, Bouteloup V, Grasset L, Planche V, Chêne G, Dufouil C, MEMENTO Study Group
Subject & Discipline J Prev Alzheimers Dis
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-42142
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »